Table 3.

Percent Change from Baseline in Lipid Parameters (ITT Population)

Lipid Parameter by Study Week	Alirocumab, Change From Baseline (%) (n = 95)	Placebo, Change From Baseline (%) (n = 50)
W24
Non–HDL-C
LS mean (SE)	−47.9 (2.6)	3.0 (3.5)
Difference (SE) vs placebo	−50.9 (4.4)
P value vs placebo	<0.0001
W21–W24
LDL-C
LS mean (SE)	−67.9 (2.8)	0.9 (3.8)
Difference (SE) vs placebo	−68.8 (4.7)
P value vs placebo	<0.0001
W24
LDL-C
LS mean (SE)	−57.4 (3.3)	4.2 (4.5)
Difference (SE) vs placebo	−61.6 (5.6)
P value vs placebo	<0.0001
Apo B
LS mean (SE)	−43.5 (2.5)	6.2 (3.4)
Difference (SE) vs placebo	−49.8 (4.2)
P value vs placebo	<0.0001
TGs
Combined estimate for mean (SE)	−9.7 (3.5)	10.7 (4.8)
Difference (SE) vs placebo	−20.4 (6.0)
P value vs placebo	0.0009
HDL-C
LS mean (SE)	2.2 (1.6)	−2.0 (2.1)
Difference (SE) vs placebo	4.1 (2.6)
P value vs placebo	0.1197
Lp(a)
Combined estimate for mean (SE)	−18.7 (3.7)	15.2 (4.9)
Difference (SE) vs placebo	−33.9 (6.2)
P value vs placebo	<0.0001
Apo A1
LS mean (SE)	4.8 (1.4)	3.1 (1.9)
Difference (SE) vs placebo	1.6 (2.4)
P value vs placebo	0.4974
TRL-C
Combined estimate for adjusted mean (SE)	−13.7 (2.9)	0.2 (4.0)
Difference (SE) vs placebo	−14.0 (5.0)
P value vs placebo	0.0052

Abbreviations: ITT, intention to treat; LS, least squares.